ARCHIVES

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

This article is from The Cancer Letter archive.

Vol. 19 No. 10 | March 5, 1993

Download PDF Visit The Full Archive

Related Articles

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

December 31, 2010

Waxman Hearing Turns Out Strong Support For Cancer Program Renewal

February 29, 1980

Long-term Follow-up Shows ADH and ALH Tissue Abnormalities Can Carry Similar Risk

January 31, 2014

HCRA Response On DRGs and Clinical Research Threat Called A “Stone Wall,” Legislative Remedy Sought

July 27, 1984

Funding opportunities listed.

February 27, 2004

SEER Program Expansion Through Cost-Sharing.

March 23, 2001